Remdesivir – CAS 1809249-37-3

€200 – €5900

Remdesivir (GS-5734) is synthesised by Santiago Lab (Prague, Czech Republic). It is one of the 5 compounds recommended by WHO for the investigation of the treatment of COVID-19. You can order remdesivir individually or as a set of 5 antivirotics recommended by WHO.

Purity (LC-MS)

99%, d.e. 95%+ | Certificate of Analysis

Package contents

Remdesivir

This compound is for research use only. We do not sell to patients.

Size	Availability	Price	Quantity
10 mg	In stock	€200	Remdesivir – CAS 1809249-37-3 quantity
25 mg	In stock	€250	Remdesivir – CAS 1809249-37-3 quantity
50 mg	In stock	€450	Remdesivir – CAS 1809249-37-3 quantity
100 mg	In stock	€600	Remdesivir – CAS 1809249-37-3 quantity
1 g	In stock	€2500	Remdesivir – CAS 1809249-37-3 quantity
2 g	In stock	€3850	Remdesivir – CAS 1809249-37-3 quantity
5 g	In stock	€5900	Remdesivir – CAS 1809249-37-3 quantity

Description
Additional information

Remdesivir

Characterisation

CAS: 1809249-37-3

IUPAC Name: 2-ethylbutyl (2S)-2-[[[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate

Other names: GS 5734; DB14761; SB19838, Remdesivir

Molecular weight: 602.58 g/mol

Molecular formula:C₂₇H₃₅N₆O₈P

Description

Remdesivir (also known as GS-5734) is synthesised by Santiago Lab (Prague, Czech Republic). It is an antiviral drug that belongs to the class of nucleotide analogues. It was mainly developed as a treatment for filovirus infections such as Ebola virus disease or Marburg virus. Subsequently, Remdesivir was found to show antiviral activity against other single-stranded RNA viruses such as respiratory syncytial virus, Nipah virus, Hendra virus, Junin virus, Lassa fever virus and the coronaviruses (including MERS and SARS viruses). Recently it is being studied as a promising medication for the treatment of COVID-19 (new SARS type virus).

Remdesivir, developed by Gilead Sciences, is an adenosine prodrug that metabolizes into its active form GS-441524 which interferes with the action of viral RNA-dependent RNA polymerase and evades proofreading by viral exoribonuclease (ExoN), causing a decrease in viral RNA production.

We are also offering active metabolites of Remdesivir: Remdesivir triphosphate, diphosphate or monophosphate.

Chemicals are distributed worldwide

Buy Remdesivir now, get your order in 48 hours

Shipping through DHL in 48 hours
Shipping worldwide for free
All compounds are safely and rigorously packed

Payment

We are sending the invoice the same day as the shipment
We are able to modify the invoice for the academic institution, so the order can be paid from grants

References

1. Wang, M.; Cao, R.; Zhang, L.; Yang, X.; Liu, J.; Xu, M.; Shi, Z.; Hu, Z.; Zhong, W.; Xiao, G., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research 2020, 30 (3), 269-271.
2. Sheahan, T. P.; Sims, A. C.; Leist, S. R.; Schäfer, A.; Won, J.; Brown, A. J.; Montgomery, S. A.; Hogg, A.; Babusis, D.; Clarke, M. O., Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nature Communications 2020, 11 (1), 1-14.
3. Lai, C.-C.; Shih, T.-P.; Ko, W.-C.; Tang, H.-J.; Hsueh, P.-R., Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. International journal of antimicrobial agents 2020, 105924.
4. Ko, W.-C.; Rolain, J.-M.; Lee, N.-Y.; Chen, P.-L.; Huang, C.-T.; Lee, P.-I.; Hsueh, P.-R., Arguments in favour of remdesivir for treating SARS-CoV-2 infections. International journal of antimicrobial agents 2020.
5. Gordon, C. J.; Tchesnokov, E. P.; Feng, J. Y.; Porter, D. P.; Gotte, M., The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. Journal of Biological Chemistry 2020, jbc. AC120. 013056.
6. de Wit, E.; Feldmann, F.; Cronin, J.; Jordan, R.; Okumura, A.; Thomas, T.; Scott, D.; Cihlar, T.; Feldmann, H., Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proceedings of the National Academy of Sciences 2020, 117 (12), 6771-6776.
7. Tchesnokov, E. P.; Feng, J. Y.; Porter, D. P.; Götte, M., Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir. Viruses 2019, 11 (4), 326.
8. Pruijssers, A. J.; Denison, M. R., Nucleoside analogues for the treatment of coronavirus infections. Current opinion in virology 2019, 35, 57-62.
9. Hoenen, T.; Groseth, A.; Feldmann, H., Therapeutic strategies to target the Ebola virus life cycle. Nature Reviews Microbiology 2019, 17 (10), 593-606.
10. Brown, A. J.; Won, J. J.; Graham, R. L.; Dinnon III, K. H.; Sims, A. C.; Feng, J. Y.; Cihlar, T.; Denison, M. R.; Baric, R. S.; Sheahan, T. P., Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral research 2019, 169, 104541.
11. Agostini, M. L.; Andres, E. L.; Sims, A. C.; Graham, R. L.; Sheahan, T. P.; Lu, X.; Smith, E. C.; Case, J. B.; Feng, J. Y.; Jordan, R., Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio 2018, 9 (2), e00221-18.
12. Siegel, D.; Hui, H. C.; Doerffler, E.; Clarke, M. O.; Chun, K.; Zhang, L.; Neville, S.; Carra, E.; Lew, W.; Ross, B.; Wang, Q.; Wolfe, L.; Jordan, R.; Soloveva, V.; Knox, J.; Perry, J.; Perron, M.; Stray, K. M.; Barauskas, O.; Feng, J. Y.; Xu, Y.; Lee, G.; Rheingold, A. L.; Ray, A. S.; Bannister, R.; Strickley, R.; Swaminathan, S.; Lee, W. A.; Bavari, S.; Cihlar, T.; Lo, M. K.; Warren, T. K.; Mackman, R. L., Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. Journal of Medicinal Chemistry 2017, 60 (5), 1648-1661.
13. Warren, T. K.; Jordan, R.; Lo, M. K.; Ray, A. S.; Mackman, R. L.; Soloveva, V.; Siegel, D.; Perron, M.; Bannister, R.; Hui, H. C.; Larson, N.; Strickley, R.; Wells, J.; Stuthman, K. S.; Van Tongeren, S. A.; Garza, N. L.; Donnelly, G.; Shurtleff, A. C.; Retterer, C. J.; Gharaibeh, D.; Zamani, R.; Kenny, T.; Eaton, B. P.; Grimes, E.; Welch, L. S.; Gomba, L.; Wilhelmsen, C. L.; Nichols, D. K.; Nuss, J. E.; Nagle, E. R.; Kugelman, J. R.; Palacios, G.; Doerffler, E.; Neville, S.; Carra, E.; Clarke, M. O.; Zhang, L.; Lew, W.; Ross, B.; Wang, Q.; Chun, K.; Wolfe, L.; Babusis, D.; Park, Y.; Stray, K. M.; Trancheva, I.; Feng, J. Y.; Barauskas, O.; Xu, Y.; Wong, P.; Braun, M. R.; Flint, M.; McMullan, L. K.; Chen, S.-S.; Fearns, R.; Swaminathan, S.; Mayers, D. L.; Spiropoulou, C. F.; Lee, W. A.; Nichol, S. T.; Cihlar, T.; Bavari, S., Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 2016, 531 (7594), 381-385.